FI77861C - Foerfarande foer framstaellning av farmakologiskt aktiva pyridazino/4,3-c/isokinoliner. - Google Patents
Foerfarande foer framstaellning av farmakologiskt aktiva pyridazino/4,3-c/isokinoliner. Download PDFInfo
- Publication number
- FI77861C FI77861C FI842586A FI842586A FI77861C FI 77861 C FI77861 C FI 77861C FI 842586 A FI842586 A FI 842586A FI 842586 A FI842586 A FI 842586A FI 77861 C FI77861 C FI 77861C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- pyridazino
- compound
- phenyl
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000008569 process Effects 0.000 title claims description 7
- 150000002537 isoquinolines Chemical class 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 23
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 claims 1
- 239000000571 coke Substances 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
- 239000002249 anxiolytic agent Substances 0.000 abstract description 3
- 230000000049 anti-anxiety effect Effects 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- AFCCQNLWUCZFJN-UHFFFAOYSA-N pyridazino[4,3-c]isoquinoline Chemical class C1=NN=C2C3=CC=CC=C3C=NC2=C1 AFCCQNLWUCZFJN-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- -1 for example Chemical group 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000001961 anticonvulsive agent Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001773 anti-convulsant effect Effects 0.000 description 7
- 229960003965 antiepileptics Drugs 0.000 description 7
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 229960003529 diazepam Drugs 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- WEFZRXGBNHFUIE-UHFFFAOYSA-N 6-chloro-3-phenylpyridazino[4,3-c]isoquinoline Chemical compound N=1N=C2C3=CC=CC=C3C(Cl)=NC2=CC=1C1=CC=CC=C1 WEFZRXGBNHFUIE-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960005152 pentetrazol Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001253 anti-conflict Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 150000001804 chlorine Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- LMKYJLQLMNZKNJ-UHFFFAOYSA-N 2-[6-(2-methoxyphenyl)-4-oxo-1h-pyridazin-3-yl]benzoic acid Chemical compound COC1=CC=CC=C1C1=CC(O)=C(C=2C(=CC=CC=2)C(O)=O)N=N1 LMKYJLQLMNZKNJ-UHFFFAOYSA-N 0.000 description 1
- LXVCCGBODKVMRP-UHFFFAOYSA-N 2-[6-(4-methoxyphenyl)-4-oxo-1h-pyridazin-3-yl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C(C=2C(=CC=CC=2)C(O)=O)=NN1 LXVCCGBODKVMRP-UHFFFAOYSA-N 0.000 description 1
- BQAVZKPCEICBRV-UHFFFAOYSA-N 2-amino-3h-isoindol-1-one Chemical class C1=CC=C2C(=O)N(N)CC2=C1 BQAVZKPCEICBRV-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- OWELJMCLPWIQCP-UHFFFAOYSA-N 3-(4-chlorophenyl)-N,N-bis(2-methoxyethyl)pyrido[3,4-f]cinnolin-6-amine Chemical compound ClC1=CC=C(C=C1)C=1N=CC2=C3C(=C(C=C2C=1)N(CCOC)CCOC)N=NC=C3 OWELJMCLPWIQCP-UHFFFAOYSA-N 0.000 description 1
- OKWVREZRQKNQAF-UHFFFAOYSA-N 3-(4-chlorophenyl)isochromeno[4,3-c]pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1C(N=N1)=CC2=C1C1=CC=CC=C1C(=O)O2 OKWVREZRQKNQAF-UHFFFAOYSA-N 0.000 description 1
- FODGRHOLEFBWMW-UHFFFAOYSA-N 3-(4-methoxyphenyl)-6-piperidin-1-ylpyridazino[4,3-c]isoquinoline Chemical compound C1=CC(OC)=CC=C1C1=CC2=NC(N3CCCCC3)=C(C=CC=C3)C3=C2N=N1 FODGRHOLEFBWMW-UHFFFAOYSA-N 0.000 description 1
- LLLYCHFUZVLFAM-UHFFFAOYSA-N 3-methylpyridazino[4,3-c]isoquinoline Chemical compound C1=CC=CC2=C(N=NC(C)=C3)C3=NC=C21 LLLYCHFUZVLFAM-UHFFFAOYSA-N 0.000 description 1
- HVBFSZRTFJZLJV-UHFFFAOYSA-N 3-phenyl-5h-pyridazino[4,3-c]isoquinolin-6-one Chemical compound N=1N=C2C3=CC=CC=C3C(=O)NC2=CC=1C1=CC=CC=C1 HVBFSZRTFJZLJV-UHFFFAOYSA-N 0.000 description 1
- VLXHLUBCYLCAFG-UHFFFAOYSA-N 5H-pyridazino[3,4-c]isoquinolin-6-one Chemical class C1=CN=NC=2NC(C=3C=CC=CC=3C=21)=O VLXHLUBCYLCAFG-UHFFFAOYSA-N 0.000 description 1
- UYGGMUGKAHTMSV-UHFFFAOYSA-N 5h-isoquinolin-6-one Chemical compound C1=NC=C2C=CC(=O)CC2=C1 UYGGMUGKAHTMSV-UHFFFAOYSA-N 0.000 description 1
- AMEOWHDHXUZNPN-UHFFFAOYSA-N 6-chloro-3-phenylpyrido[3,4-f]cinnoline Chemical compound ClC=1C=C2C=C(N=CC2=C2C=1N=NC=C2)C1=CC=CC=C1 AMEOWHDHXUZNPN-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GBSPXMBSGOQFOF-UHFFFAOYSA-N C1=CN=CC2=C3C=CN=NC3=C(C=C21)Cl Chemical compound C1=CN=CC2=C3C=CN=NC3=C(C=C21)Cl GBSPXMBSGOQFOF-UHFFFAOYSA-N 0.000 description 1
- GTEWFFFUIUEVEQ-UHFFFAOYSA-N C1CCN(C1)C2=C3C(=C4C=NC(=CC4=C2)C5=CC=CC=C5)C=CN=N3 Chemical compound C1CCN(C1)C2=C3C(=C4C=NC(=CC4=C2)C5=CC=CC=C5)C=CN=N3 GTEWFFFUIUEVEQ-UHFFFAOYSA-N 0.000 description 1
- HLJKEMUSVFQLHK-UHFFFAOYSA-N COC1=CC=C(C=C1)C2=CC3=CC(=C4C(=C3C=N2)C=CN=N4)N5CCOCC5 Chemical compound COC1=CC=C(C=C1)C2=CC3=CC(=C4C(=C3C=N2)C=CN=N4)N5CCOCC5 HLJKEMUSVFQLHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- JAGZUIGGHGTFHO-UHFFFAOYSA-N Ethyl 3-phenylpropanoate Chemical compound CCOC(=O)CCC1=CC=CC=C1 JAGZUIGGHGTFHO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LHRMEDQPLRNFBA-UHFFFAOYSA-N ethyl 3-(4-methoxyphenyl)-3-[(3-oxo-1h-isoindol-2-yl)imino]propanoate Chemical compound C1C2=CC=CC=C2C(=O)N1N=C(CC(=O)OCC)C1=CC=C(OC)C=C1 LHRMEDQPLRNFBA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NGFCTYXFMDWFRQ-UHFFFAOYSA-N isoquinolin-6-amine Chemical compound C1=NC=CC2=CC(N)=CC=C21 NGFCTYXFMDWFRQ-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2201383 | 1983-07-12 | ||
| IT22013/83A IT1194309B (it) | 1983-07-12 | 1983-07-12 | Derivati 3-fenil-piridazino (4,3-c) isochinolinici |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI842586A0 FI842586A0 (fi) | 1984-06-27 |
| FI842586A7 FI842586A7 (fi) | 1985-01-13 |
| FI77861B FI77861B (fi) | 1989-01-31 |
| FI77861C true FI77861C (fi) | 1989-05-10 |
Family
ID=11190189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI842586A FI77861C (fi) | 1983-07-12 | 1984-06-27 | Foerfarande foer framstaellning av farmakologiskt aktiva pyridazino/4,3-c/isokinoliner. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4716159A (OSRAM) |
| EP (1) | EP0134461B1 (OSRAM) |
| JP (1) | JPS6048989A (OSRAM) |
| KR (1) | KR910005849B1 (OSRAM) |
| AT (1) | ATE30157T1 (OSRAM) |
| AU (1) | AU570057B2 (OSRAM) |
| CA (1) | CA1229602A (OSRAM) |
| DE (1) | DE3466690D1 (OSRAM) |
| DK (1) | DK323484A (OSRAM) |
| ES (1) | ES534200A0 (OSRAM) |
| FI (1) | FI77861C (OSRAM) |
| GR (1) | GR82126B (OSRAM) |
| HU (1) | HU193687B (OSRAM) |
| IL (1) | IL72308A (OSRAM) |
| IT (1) | IT1194309B (OSRAM) |
| NO (1) | NO160613C (OSRAM) |
| NZ (1) | NZ208864A (OSRAM) |
| PH (1) | PH22631A (OSRAM) |
| PT (1) | PT78891B (OSRAM) |
| ZA (1) | ZA844970B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0633277B2 (ja) * | 1986-01-10 | 1994-05-02 | 吉富製薬株式会社 | ベンゾチオピラノ〔４，３−ｃ〕ピリダジン化合物 |
| DE3814552A1 (de) * | 1988-04-29 | 1989-11-09 | Hoechst Ag | 9-oxo-1,9a-10-triaza-9-hydro-anthracen- verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbmittel |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4062958A (en) * | 1976-09-22 | 1977-12-13 | American Cyanamid Company | Method of treating anxiety and compositions therefor |
-
1983
- 1983-07-12 IT IT22013/83A patent/IT1194309B/it active
-
1984
- 1984-06-26 GR GR75128A patent/GR82126B/el unknown
- 1984-06-27 FI FI842586A patent/FI77861C/fi not_active IP Right Cessation
- 1984-06-29 DE DE8484107554T patent/DE3466690D1/de not_active Expired
- 1984-06-29 AT AT84107554T patent/ATE30157T1/de not_active IP Right Cessation
- 1984-06-29 EP EP84107554A patent/EP0134461B1/en not_active Expired
- 1984-06-29 ZA ZA844970A patent/ZA844970B/xx unknown
- 1984-06-29 DK DK323484A patent/DK323484A/da not_active Application Discontinuation
- 1984-07-03 AU AU30221/84A patent/AU570057B2/en not_active Ceased
- 1984-07-05 IL IL72308A patent/IL72308A/xx unknown
- 1984-07-10 JP JP59141572A patent/JPS6048989A/ja active Granted
- 1984-07-11 PH PH30962A patent/PH22631A/en unknown
- 1984-07-11 HU HU842715A patent/HU193687B/hu unknown
- 1984-07-11 KR KR1019840004038A patent/KR910005849B1/ko not_active Expired
- 1984-07-11 PT PT78891A patent/PT78891B/pt not_active IP Right Cessation
- 1984-07-11 NZ NZ208864A patent/NZ208864A/xx unknown
- 1984-07-11 ES ES534200A patent/ES534200A0/es active Granted
- 1984-07-11 NO NO842825A patent/NO160613C/no unknown
- 1984-07-11 CA CA000458578A patent/CA1229602A/en not_active Expired
-
1986
- 1986-07-30 US US06/891,815 patent/US4716159A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0559915B2 (OSRAM) | 1993-09-01 |
| PT78891B (en) | 1986-10-23 |
| ATE30157T1 (de) | 1987-10-15 |
| ES8600289A1 (es) | 1985-06-01 |
| JPS6048989A (ja) | 1985-03-16 |
| NO160613C (no) | 1989-05-10 |
| ES534200A0 (es) | 1985-06-01 |
| FI842586A7 (fi) | 1985-01-13 |
| PT78891A (en) | 1984-08-01 |
| GR82126B (OSRAM) | 1984-12-13 |
| DE3466690D1 (de) | 1987-11-12 |
| NO160613B (no) | 1989-01-30 |
| ZA844970B (en) | 1985-03-27 |
| AU3022184A (en) | 1985-01-17 |
| IL72308A (en) | 1987-11-30 |
| FI842586A0 (fi) | 1984-06-27 |
| FI77861B (fi) | 1989-01-31 |
| DK323484A (da) | 1985-01-13 |
| CA1229602A (en) | 1987-11-24 |
| NZ208864A (en) | 1988-06-30 |
| IT1194309B (it) | 1988-09-14 |
| HU193687B (en) | 1987-11-30 |
| US4716159A (en) | 1987-12-29 |
| PH22631A (en) | 1988-10-28 |
| KR850001209A (ko) | 1985-03-16 |
| KR910005849B1 (ko) | 1991-08-05 |
| IT8322013A0 (it) | 1983-07-12 |
| DK323484D0 (da) | 1984-06-29 |
| EP0134461A1 (en) | 1985-03-20 |
| AU570057B2 (en) | 1988-03-03 |
| HUT34975A (en) | 1985-05-28 |
| EP0134461B1 (en) | 1987-10-07 |
| IL72308A0 (en) | 1984-11-30 |
| NO842825L (no) | 1985-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI92067C (fi) | Menetelmä valmistaa terapeuttisesti aktiivisia mono- tai disubstituoituja (imidatsol-4-yyli)metyylipyrido/4,3-b/indol- ja atsepino/4,3-b/indol-1-oneja | |
| EP0362695B1 (de) | Pyrrolocarbazol-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel | |
| JPH08505881A (ja) | キノリンアミンの製造方法 | |
| NO309424B1 (no) | Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som <alfa>1-adrenergiske reseptorantagonister | |
| NO851862L (no) | Fremgangsmaate ved fremstilling av nye pyrrolobenzimidazoler | |
| KR20120083452A (ko) | 피롤로［2,3-ｄ］피리미딘 화합물 | |
| RS64654B1 (sr) | Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom | |
| US20230303578A1 (en) | Preparation method for pyrrolopyrimidine compound | |
| KR20100014413A (ko) | 5-ｈｔ6 수용체 친화력을 갖는 6' 치환된 인돌 및 인다졸 유도체 | |
| NO313963B1 (no) | 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater | |
| FI77861C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiva pyridazino/4,3-c/isokinoliner. | |
| EP4633739A1 (en) | Compounds and composition for targeting tp53-y220c mutants | |
| MXPA03008269A (es) | Derivados quimicos y su aplicacion como agente antitelomerasa. | |
| Culbertson et al. | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships | |
| IE922342A1 (en) | Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics | |
| NO832151L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive pyrazolo-pyridin-derivater | |
| US6730694B1 (en) | sPLA2 inhibitors | |
| Maruoka et al. | Synthesis of 5, 6‐dihydrothieno (and furo) pyrimidines bearing an active methine group at the 4‐position | |
| JP2004505982A (ja) | 新規なｓＰＬＡ２インヒビター | |
| AU2002219220B2 (en) | Process for the preparation of (3-cyano-1H-indol-7-YL)(4-(4-fluorophenethyl)piperazin-1-YL)-methanone and salts thereof | |
| Maruoka et al. | An efficient synthesis of 4‐alkoxy‐5, 6‐dihydro‐furo (and‐thieno)[2, 3‐d] pyrimidines using zinc chloride/triethylamine reagent system | |
| AU2002219220A1 (en) | Process for the preparation of (3-cyano-1H-indol-7-YL)(4-(4-fluorophenethyl)piperazin-1-YL)-methanone and salts thereof | |
| EP0115920A2 (en) | Pyrazino(2',3'-3,4)pyrido(1,2-a) indole derivatives | |
| Attanasi et al. | Study of the reaction between conjugated azoalkenes and α-unsubstituted-or α-substituted-β-dicarboxylate derivatives: an improved preparation of unknown polyfunctionalized 1-amino-1 H-pyrrol-2 (3 H)-ones | |
| WO2025151549A1 (en) | Pyrido[3,2-b]indole-3-carbonitrile compounds and composition for targeting tp53-y220c mutants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: GRUPPO LEPETIT S.P.A. |